NCT03516812View on ClinicalTrials.gov

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

March 5, 2021

Study Completion Date

April 12, 2024

Conditions
Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Olaparib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Survey Administration

Ancillary studies

DRUG

Testosterone Enanthate

Given IM

DRUG

Testosterone Cypionate

Given IM

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

University of Washington

OTHER